Investing in our Long-Term Growth

The Exact Sciences team highlighted the enormous strides we’re making toward our mission of eradicating colon cancer when we recently released preliminary fourth quarter and full-year 2017 results. During the year, approximately 571,000 Cologuard tests were completed, a year-over-year increase of 134 percent. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2017. The total number of providers who have ordered Cologuard since its launch increased to nearly 102,000.

Read More

Topics: Company

Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017


- 11,000 new providers ordered Cologuard during the fourth quarter of 2017

MADISON, Wis., Jan. 7, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $86.9 million and $87.9 million for the fourth quarter ended Dec. 31, 2017, an increase of 148 percent from the same quarter of 2016. The company completed approximately 176,000 Cologuard tests during the fourth quarter of 2017, 115-percent growth from the same period of 2016.

Read More

Topics: Press Releases